According to the latest report by IMARC Group, titled “Tourette Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033”, the global tourette syndrome market size is witnessing steady growth. Tourette Syndrome (TS) refers to a neurological disorder that is characterized by repetitive, involuntary movements and vocalizations called tics. Movement tics include blinking, facial grimacing, shoulder shrugging, and jerking of limbs, while vocal tics involve grunting, throat clearing, and repeated phrases. It is common for TS symptoms to begin in childhood, but symptoms can vary in severity throughout life, as TS symptoms must be present for at least a year before age 18 to be diagnosed. The symptoms of TS can negatively affect an individual's day-to-day functioning, including concentration, communication, and motor control as well as co-occurring conditions, such as attention-deficit/hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD). However, the usage of medication, therapy, and support from family and doctors may help individuals with TS manage their symptoms.
Global Tourette Syndrome Market Trends:
The global market is majorly driven by the increasing prevalence of undiagnosed Tourette syndrome in infants. In line with this, the rising focus on early diagnosis and preventive care practices are also acting as a significant growth-inducing factor for the market. Moreover, continual technological advancements in TS therapeutics, such as deep brain stimulation and transcranial magnetic stimulation therapies, are providing an impetus to the market. Besides this, favorable government initiatives supporting better healthcare infrastructure, along with various awareness programs for patients with TS, is also propelling the market growth. Additionally, the increasing awareness of the impact of Tourette syndrome on patients and their families is propelling the demand for more effective drugs and therapies. The market is further fueled by the rising number of clinical trials and the emergence of new pipeline drugs with minimal side effects. Furthermore, growing investments and funding for research into the root causes and treatment options of TS, along with the development of new medications and therapies, are creating a positive outlook for the market. Apart from this, the shifting preference toward pharmacological treatments from non-pharmacological therapies to facilitate better controlling of TS symptoms is impacting the market positively.
- Based on the marketed products, the market has been segmented into in-market drugs (Abilify (Aripiprazole) - Bristol-Myers Squibb/Otsuka Pharmaceutical, Haloperidol, and Pimozide) and late-stage pipeline drugs (Deutetrabenazine - Teva Pharmaceutical, Ecopipam - Emalex Biosciences, SCI110 - SciSparc, and Valbenazine - Neurocrine Biosciences).
- On the geographical front, the market has been segregated into the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan.
- This research study also offers a thorough overview of late-stage pipeline candidates and currently marketed medications for Tourette syndrome.
- The study also offers a thorough overview of the treatment practices for Tourette syndrome, the share of specific therapies, and the performance of key market players.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800